KDIGO

KDIGO Direct – September 2022

The latest news and updates from KDIGO
September 2022
KDIGO Prepares for Major Upcoming Milestones

KDIGO is preparing for an action-packed season with a series of key meetings, conferences, and major publications on the way.

The KDIGO Executive Committee will convene in London this September for the second of its twice-annual meetings. This meeting will include the election of new Executive Committee members for 2023, prioritization of upcoming KDIGO Conference and Guideline topics, as well as discussion and voting on key business matters and organizational initiatives.

KDIGO will hold its next Controversies Conference on the Role of Complement in Kidney Disease in Florence, Italy in September, co-chaired by Richard Smith, MD (United States), and Marina Vivarelli, MD (Italy). This conference will gather a global panel of multidisciplinary clinical and scientific expertise and a motivated group of patient representatives to define the role of complement in a spectrum of kidney diseases including glomerular disorders and diabetic nephropathy.

A number of major KDIGO publications are also on the way, including two major Guideline Updates. The update to the Clinical Practice Guideline for the Management of Diabetes in Chronic Kidney Disease (CKD) will publish online in October in Kidney International. The Clinical Practice Guideline for the Prevention, Diagnosis, Evaluation, and Treatment of Hepatitis C in CKD is currently scheduled to publish online in November in Kidney International. Guideline publication dates are subject to change based on schedule changes made by the publisher.

Another major milestone for KDIGO will be the publication of a “Joint Statement on Diabetes and CKD” authored by KDIGO and the American Diabetes Association (ADA), and targeted for publication by end of 2022. KDIGO also looks forward to the publication of the “Joint Statement on Blood Pressure Measurement,” written in collaboration with the American Heart Association (AHA), the European Society of Hypertension (ESC), and other hypertension organizations, with publication plans underway.

With numerous major publications and events on the horizon in quick succession, KDIGO looks forward to an exciting season packed with resources for the global nephrology community.
Upcoming Events and Webinars
Episode 4 of the KDIGO IgAN & FSGS Series: “Management, Treatment & Recommendations for Future Research in IgAN”

Tuesday, September 20, 1o:00 AM EDT/4:00 PM CEST

Join us for Episode 4 in the KDIGO IgAN & FSGS Webinar Series, Management, Treatment & Recommendations for Future Research in FSGS, on Tuesday, September 20, at 10:00 AM EDT, 4:00 PM CEST.

In Episode 4, Ladan Zand, MD, and Jai Radhakrishnan, MD, will discuss the management and treatment of FSGS, including initial treatment of primary FSGS, treatment of steroid-resistant FSGS, and how to approach and manage relapse. This webinar will also explore what’s ahead in FSGS treatment and recommendations for future research. This webinar will also feature a companion Tweetorial by Edgar V. Lerma, MD. Learn more and register.
17th Annual Scientific Meeting of the Cardiorenal Forum
Pre-ASM Satellite Symposium Webinar, “Treatment Advances in Cardiorenal Disease”
Thursday, October 6, Broadcast twice: 12.30 PM BST & 18:00 BST (GMT +1)

 

As part of activities for their 17th annual scientific meeting (ASM), the Cardiorenal Forum is providing a free pre-recorded webinar, for healthcare professionals, particularly those who are unable to attend the in-person meeting on Friday, October 7.

In Treatment Advances in Cardiorenal Disease, David Wheeler, MD (United Kingdom), Patricia Campbell, MD (United Kingdom), and Debasish Banerjee, MD (United Kingdom) provide an update on the use of SGLT2 inhibitors in heart failure and chronic kidney disease (CKD), approaches to treating hyperkalaemia, as well as an overview of developments in mineralocorticoid antagonists. This webinar will also cover lessons from recent trials, evolving multidisciplinary guidelines, and future care pathways. Learn more and register.
New Resources

KDIGO Glomerular Diseases Guideline Key Takeaways for Clinicians

The KDIGO Glomerular Diseases Guideline Key Takeaways for Clinicians are now available for two additional Guideline chapters, Infection-related Glomerulonephritis, and General Principles.

Visit the KDIGO Glomerular Diseases Guideline Website to download the new Key Takeaways. You can also download additional Key Takeaways for each of the chapters in the KDIGO Glomerular Diseases Guideline. These include ANCA, Anti-GBM, Complement (ICMG), FSGS, IgAN, lupus nephritis, membranous nephropathy, minimal change disease, and nephrotic syndrome in children.

Recording: Episode 4 of the ISN-KDIGO Complement in GN Series, “Role of Complement Beyond Glomerulonephritis (Transplantation/DKD)”

The recording is now available for Episode 4 in the ISN-KDIGO Webinar Series on Complement in GN, Role of Complement Beyond Glomerulonephritis (Transplantation, DKD).

In this webinar, Julia Weinmann-Menke, MD (Germany), Sydney Tang, MD (China), and Leonardo Riella, MD (United States), present clinical and experimental evidence highlighting the potential of targeting complement as a therapeutic approach to DKD.  Watch the recording.

Recording: Episode 3 of the KDIGO IgAN & FSGS Series, “Management, Treatment & Recommendations for Future Research in IgAN”

The recording is now available for Episode 3 in the KDIGO IgAN & FSGS Webinar Series, Pathophysiology & Diagnosis of FSGS.

In Episode 3, Keisha Gibson, MD (United States), and Brad Rovin, MD (United States), discuss the pathophysiology and diagnosis of FSGS, reviewing the classification, pathology, and definitions of FSGS. This webinar also addresses the differentiation between primary and secondary FSGS, the proper workup of FSGS lesion, and the utility of genetic testing (e.g., APOL1 risk variants). Watch the recording.

Recording: Episode 3 of the ISN-KDIGO Complement in GN Series, “What’s New in the Management and Treatment of Glomerulonephritis: A look at IgAN and MN”

 

The recording is now available for Episode 3 in the ISN-KDIGO Webinar Series on Complement in GN, “What’s New in the Management and Treatment of Glomerulophephritis: A Look at IgAN and MN.

In this webinar, Heather Reich, MD (Canada) Vivekanand Jha, MD (India), and Marina Vivarelli, MD (Italy) review the results of clinical trials of new supportive and immunosuppressive treatments, highlighting treatment challenges and unmet clinical needs. This webinar also includes an overview of how a new understanding of the pathophysiology of IgAN has broadened opportunities for trials of novel targeted therapies for this important global cause of kidney disease.
Watch the recording.
CME: Diabetic Kidney Disease New Ways Forward

Now available on-demand is a new KDIGO and PlatformQ Health CME program,
Diabetic Kidney Disease: New Ways Forward, with Ralph DeFronzo, MD (United States), and Katherine Tuttle, MD (United States). Join a panel of nephrology and endocrinology experts for an in-depth look at the combined role of eGFR and albuminuria as a marker of disease, as prognostic factors, and as a measure of response to therapy.

To ensure appropriate patients have access to breakthrough therapies, Dr. DeFronzo and Dr. Tuttle review the mechanisms of action and safety and efficacy profiles of new and emerging agents, including SGLT2 inhibitors and new-generation mineralocorticoid receptor antagonists.
Learn more and register.
Recording: Explore a Novel Approach to the Treatment of IgA Nephropathy
Now available on-demand is a PlatformQ Health program, Explore a Novel Approach to the Treatment of IgA Nephropathy. In this program, Jonathan Barratt, PhD, FRCP (United Kingdom), discusses FDA-approved treatment of IgA nephropathy including the mechanism of action, as well as safety and efficacy data. Register.
About KDIGO
KDIGO is a Belgian foundation committed to developing and implementing nephrology guidelines that improve patient outcomes on a global basis. KDIGO is independent, volunteer-led, self-managed, and accountable to the public and the patients it serves. Learn More.
Exit mobile version